Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012;18(10):1434-45.
doi: 10.2174/138161212799504858.

Non-systemic drugs: a critical review

Dominique Charmot  1
Affiliations
Free PMC article
Review

Non-systemic drugs: a critical review

Dominique Charmot. Curr Pharm Des. 2012.
Free PMC article

Abstract

Non-systemic drugs act within the intestinal lumen without reaching the systemic circulation. The first generation included polymeric resins that sequester phosphate ions, potassium ions, or bile acids for the treatment of electrolyte imbalances or hypercholesteremia. The field has evolved towards non-absorbable small molecules or peptides targeting luminal enzymes or transporters for the treatment of mineral metabolism disorders, diabetes, gastrointestinal (GI) disorders, and enteric infections. From a drug design and development perspective, non-systemic agents offer novel opportunities to address unmet medical needs while minimizing toxicity risks, but also present new challenges, including developing a better understanding and control of non-transcellular leakage pathways into the systemic circulation. The pharmacokinetic-pharmacodynamic relationship of drugs acting in the GI tract can be complex due to the variability of intestinal transit, interaction with chyme, and the complex environment of the surface epithelia. We review the main classes of nonabsorbable agents at various stages of development, and their therapeutic potential and limitations. The rapid progress in the identification of intestinal receptors and transporters, their functional characterization and role in metabolic and inflammatory disorders, will undoubtedly renew interest in the development of novel, safe, non-systemic therapeutics.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Mode of action of non-absorbed drugs. Class I: sequestering agent (exemplified by an anion-exchange polymer); Class II: Ligands of soluble intestinal enzymes; Class III: exogenous enzymes; Class IV: Minimally absorbed and rapidly metabolized drugs (also referred to as soft drugs); Class V: Ligands of apical targets. (The modes of action of each class are described in the text)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bodor N, Buchwald P. Recent advances in retrometabolic drug design (RMDD) and development. Pharmazie. 2010;65:395–403. - PubMed
    1. Bodor , Buchwald P. Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolites. Mol.Biotechnol. 2004;26:123–32. - PubMed
    1. Bodor N. Retrometabolic drug design--novel aspects, future directions. Pharmazie. 2001;56(Suppl 1):S67–74. - PubMed
    1. Bodor N, Buchwald P. Soft drug design: general principles and recent applications. Med.Res.Rev. 2000;20:58–101. - PubMed
    1. Lennernas H. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica. 2007;37:1015–51. - PubMed

MeSH terms

Substances

LinkOut - more resources